Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company’s ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
तुलना करने के लिए मीट्रिक्स | CARM | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधCARMपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −0.5x | −2.3x | −0.7x | |
PEG अनुपात | −0.01 | 0.01 | 0.00 | |
क़ीमत/बुक | −3.0x | 3.0x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 1.6x | 5.5x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 92.8% | 44.1% | |
उचित मूल्य अपसाइड | अनलॉक करें | 8.9% | 8.2% | अनलॉक करें |